Stage III Multiple Myeloma, Stage II Multiple Myeloma, Stage I Multiple Myeloma
Conditions
Keywords
Maintenance, Consolidation
Brief summary
This randomized phase II trial studies how well giving bortezomib with or without combination chemotherapy works as consolidation therapy in patients with newly diagnosed multiple myeloma who have completed stem cell transplant. Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as cyclophosphamide, dexamethasone, and lenalidomide, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. It is not yet known whether giving bortezomib is more effective with or without combination chemotherapy in the post transplant setting.
Detailed description
PRIMARY OBJECTIVES: I. To compare the stringent complete response (sCR) rate after 12 cycles among arms. SECONDARY OBJECTIVES: I. To compare progression-free and overall survival among arms. II. To describe the adverse event profile of each arm. TERTIARY OBJECTIVES: I. To compare sCR after 6 cycles and 24 cycles and quality of life among arms. OUTLINE: Patients are randomized to 1 of 3 treatment arms. ARM A: Patients receive bortezomib subcutaneously (SC) on days 1 and 15 of courses 1-12 and day 1 of courses 13-24. ARM B: Patients receive bortezomib SC as in Arm A, cyclophosphamide orally (PO) on days 1 and 15 of courses 1-12 and day 1 of courses 13-24, and dexamethasone PO on days 1 and 15 of courses 1-12 and day 1 of courses 13-24. ARM C: Patients receive bortezomib SC as in Arm A and lenalidomide PO once daily (QD) on days 1-28. In all arms, treatment continues every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up every 6 months for 3 years.
Interventions
DRUGbortezomib
Given SC
DRUGcyclophosphamide
Given PO
DRUGlenalidomide
Given PO
OTHERlaboratory biomarker analysis
Correlative studies
DRUGdexamethasone
Given PO
PROCEDUREquality-of-life assessment
Ancillary studies
Sponsors
Mayo Clinic
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Creatinine =\< 2 mg/dL * Absolute neutrophil count (ANC) \>= 1000/mm\^3 * Platelet count \>= 75000/mm\^3 * Hemoglobin \>= 8.0 g/dL * Total bilirubin =\< 1.5 x upper limit of normal (ULN) * Treated myeloma: Prior induction therapy (any) and followed by autologous stem cell transplantation * Measurable disease at initial diagnosis, pre-stem cell transplant (SCT) or post-SCT of multiple myeloma as defined by at least ONE of the following: * Serum monoclonal protein \>= 0.5 g/dL * \> 200 mg of monoclonal protein in the urine on 24 hour electrophoresis * Serum immunoglobulin free light chain \>= 5 mg/dL AND abnormal serum immunoglobulin kappa to lambda free light chain ratio * Monoclonal bone marrow plasmacytosis \>= 30% (evaluable disease) * Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1 or 2 * \< 120 days post SCT with no evidence of relapse or progression prior to registration * Provide voluntary informed written consent before performance of any study-related procedure not part of normal medical care, with the understanding that consent may be withdrawn by the subject at any time without prejudice to future medical care * Negative serum pregnancy test done =\< 7 days prior to registration, for women of childbearing potential only * Willing to return to enrolling institution for follow-up during the active monitoring phase of the study * Ability to complete questionnaire(s) by themselves or with assistance * Female patients who: * Are postmenopausal for at least 1 year before the screening visit, OR * Are surgically sterile, OR * If they are of childbearing potential, agree to practice 2 effective methods of contraception, at the same time, from the time of signing the informed consent through 30 days after the last dose of study treatment, OR agree to completely abstain from heterosexual intercourse * Male patients, even if surgically sterilized (ie, status postvasectomy), who: * Agree to practice effective barrier contraception during the entire study treatment period and through 30 days after the last dose of study treatment, OR * Agree to completely abstain from heterosexual intercourse
Exclusion criteria
* Other active malignancy =\< 3 years prior to registration; EXCEPTIONS: Non-melanotic skin cancer or carcinoma-in-situ of the cervix; NOTE: If there is a history of prior malignancy, they must not be receiving other specific treatment for their cancer * Other co-morbidity which would interfere with patient's ability to participate in trial, e.g. uncontrolled infection, uncompensated heart or lung disease * Other concurrent chemotherapy, radiotherapy, or any ancillary therapy considered investigational; NOTE: Bisphosphonates are considered to be supportive care rather than therapy, and are thus allowed while on protocol treatment * Known to be human immunodeficiency virus (HIV), hepatitis C virus (HCV) or hepatitis B virus positive (HBV+) * Hypersensitivity to study drugs, boron or mannitol * Patient refractory to bortezomib (defined as patients who progressed while on bortezomib or within 60 days of receiving bortezomib) * Any serious medical or psychiatric condition that would prevent the subject from complying with the protocol treatment and procedures * Grade \>= 2 peripheral neuropathy * Myocardial infarction within 6 months prior to enrollment or has New York Heart Association (NYHA) Class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities; prior to study entry, any electrocardiogram (ECG) abnormality at screening must be documented by the investigator as not medically relevant * Participation in clinical trials with other investigational agents not included in this trial, within 14 days of the start of this trial and throughout the duration of this trial * Radiation therapy within 3 weeks before randomization; enrollment of subjects who require concurrent radiotherapy (which must be localized in its field size) should be deferred until the radiotherapy is completed and 3 weeks have elapsed since the last date of therapy * Female patients who are lactating or pregnant
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Proportion of Patients Experiencing a Stringent Complete Response (sCR) After 12 Cycles, 24 Months | 24 months | Estimated by the number of sCRs divided by the total number of evaluable patients in each arm. Exact binomial confidence intervals for the true sCR rate will be calculated by arm. Stringent complete response (sCR) is defined as a complete response plus normal serum free light chain ratio and the absence of clonal cells in bone marrow by flow cytometry. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Survival Time | From registration to death due to any cause, assessed up to 3 years | The distribution of survival time will be estimated by arm using the method of Kaplan-Meier. |
| Progression-free Survival | From registration to the earliest date of documentation of disease progression or death due to any cause, assessed up to 3 years | The distribution of progression-free survival will be estimated by arm using the method of Kaplan-Meier. |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Arm A Patients receive bortezomib SC on days 1 and 15 of courses 1-12 and day 1 of courses 13-24. | 1 |
| Arm B Patients receive bortezomib SC as in Arm A, cyclophosphamide PO on days 1 and 15 of courses 1-12 and day 1 of courses 13-24, and dexamethasone PO on days 1 and 15 of courses 1-12 and day 1 of courses 13-24. | 1 |
| Arm C Patients receive bortezomib SC as in Arm A and lenalidomide PO QD on days 1-28. | 1 |
| Total | 3 |
Baseline characteristics
| Characteristic | Arm A | Arm B | Arm C | Total |
|---|---|---|---|---|
| Age, Continuous | 54 Years | 45 Years | 50 Years | 50 Years |
| Ethnicity (NIH/OMB) Hispanic or Latino | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 1 Participants | 1 Participants | 1 Participants | 3 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Had Prior Treatment | 1 participants | 1 participants | 1 participants | 3 participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Black or African American | 0 Participants | 1 Participants | 0 Participants | 1 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) White | 1 Participants | 0 Participants | 1 Participants | 2 Participants |
| Region of Enrollment United States | 1 participants | 1 participants | 1 participants | 3 participants |
| Sex: Female, Male Female | 0 Participants | 1 Participants | 1 Participants | 2 Participants |
| Sex: Female, Male Male | 1 Participants | 0 Participants | 0 Participants | 1 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk |
|---|---|---|---|
| deaths Total, all-cause mortality | — / — | — / — | — / — |
| other Total, other adverse events | 1 / 1 | 1 / 1 | 1 / 1 |
| serious Total, serious adverse events | 1 / 1 | 0 / 1 | 1 / 1 |
Outcome results
Primary
Proportion of Patients Experiencing a Stringent Complete Response (sCR) After 12 Cycles, 24 Months
Estimated by the number of sCRs divided by the total number of evaluable patients in each arm. Exact binomial confidence intervals for the true sCR rate will be calculated by arm. Stringent complete response (sCR) is defined as a complete response plus normal serum free light chain ratio and the absence of clonal cells in bone marrow by flow cytometry.
Time frame: 24 months
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Arm A | Proportion of Patients Experiencing a Stringent Complete Response (sCR) After 12 Cycles, 24 Months | 100 percentage of participants |
| Arm B | Proportion of Patients Experiencing a Stringent Complete Response (sCR) After 12 Cycles, 24 Months | 0 percentage of participants |
| Arm C | Proportion of Patients Experiencing a Stringent Complete Response (sCR) After 12 Cycles, 24 Months | 100 percentage of participants |
Secondary
Progression-free Survival
The distribution of progression-free survival will be estimated by arm using the method of Kaplan-Meier.
Time frame: From registration to the earliest date of documentation of disease progression or death due to any cause, assessed up to 3 years
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Arm A | Progression-free Survival | NA Months to Progression |
| Arm B | Progression-free Survival | 9.2 Months to Progression |
| Arm C | Progression-free Survival | NA Months to Progression |
Secondary
Survival Time
The distribution of survival time will be estimated by arm using the method of Kaplan-Meier.
Time frame: From registration to death due to any cause, assessed up to 3 years
Population: All patients are still alive
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Arm A | Survival Time | NA Months to death |
| Arm B | Survival Time | NA Months to death |
| Arm C | Survival Time | NA Months to death |